Johnson & Johnson (NYSE:JNJ) says it has settled most of the lawsuits in the anti-psychotic drug Risperdal cases and has recorded $800 million in expenses in connection with the agreement. The medical ...
This study examines the plan characteristics associated with generic risperidone use and spending and adherence outcomes associated with use among Medicare Advantage Part D beneficiaries. Objectives: ...
Johnson & Johnson's schizophrenia drug Risperdal at Skenderian Apothecary in Cambridge, Massachusetts, on Jan. 23, 2007. Photo: JB Reed/Bloomberg News. The Pennsylvania Supreme Court has ruled that ...
Johnson & Johnson's schizophrenia drug Risperdal at Skenderian Apothecary in Cambridge, Massachusetts, on Jan. 23, 2007. Photo: JB Reed/Bloomberg News. The Pennsylvania Supreme Court has ruled that ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant ...
Please provide your email address to receive an email when new articles are posted on . An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback